Equities Analysts Offer Predictions for ADAP FY2024 Earnings

Adaptimmune Therapeutics plc (NASDAQ:ADAP) – Investment analysts at HC Wainwright boosted their FY2024 earnings estimates for shares of Adaptimmune Therapeutics in a report issued on Thursday, November 14th. HC Wainwright analyst A. He now forecasts that the biotechnology company will earn ($0.12) per share for the year, up from their prior estimate of ($0.30). HC Wainwright has a “Buy” rating and a $3.50 price objective on the stock. The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.19) per share. HC Wainwright also issued estimates for Adaptimmune Therapeutics’ FY2025 earnings at ($0.54) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at ($0.12) EPS and FY2028 earnings at $0.06 EPS.

A number of other research firms also recently weighed in on ADAP. StockNews.com downgraded Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Guggenheim cut their price target on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $3.16.

Adaptimmune Therapeutics Trading Up 13.4 %

Shares of NASDAQ ADAP opened at $0.67 on Monday. Adaptimmune Therapeutics has a fifty-two week low of $0.42 and a fifty-two week high of $2.05. The firm has a market capitalization of $172.67 million, a P/E ratio of -3.07 and a beta of 2.26. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. The company’s 50 day simple moving average is $0.86 and its 200 day simple moving average is $1.02.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC raised its position in shares of Adaptimmune Therapeutics by 130.4% during the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 98,581 shares during the period. FMR LLC increased its stake in Adaptimmune Therapeutics by 3.0% during the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock worth $1,655,000 after purchasing an additional 50,419 shares in the last quarter. Baillie Gifford & Co. raised its holdings in Adaptimmune Therapeutics by 10.7% during the 3rd quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock worth $15,944,000 after buying an additional 1,626,657 shares during the period. GSA Capital Partners LLP bought a new position in Adaptimmune Therapeutics in the third quarter valued at approximately $95,000. Finally, Fullcircle Wealth LLC acquired a new position in shares of Adaptimmune Therapeutics in the third quarter valued at approximately $33,000. 31.37% of the stock is owned by institutional investors and hedge funds.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.